{
    "clinical_study": {
        "@rank": "78780", 
        "acronym": "S 303 RBC", 
        "arm_group": [
            {
                "arm_group_label": "S303 Red Blood Cells (RBCs)", 
                "arm_group_type": "Experimental", 
                "description": "The subjects will be randomly assigned to the sequence of administration of Test and Control RBCs; eligible subjects are randomly assigned to receive Test RBCs followed by Control RBCs, or Control RBCs followed by Test RBCs."
            }, 
            {
                "arm_group_label": "Conventional, Untreated Red Blood Cells (RBCs)", 
                "arm_group_type": "Active Comparator", 
                "description": "The subjects will be randomly assigned to the sequence of administration of Test and Control RBCs; eligible subjects are randomly assigned to receive Test RBCs followed by Control RBCs, or Control RBCs followed by Test RBCs."
            }
        ], 
        "brief_summary": {
            "textblock": "The objective of this study is to assess the post-infusion viability of S-303 Red Blood\n      Cells (RBC) by measuring the 24 hour post-infusion recovery and lifespan of autologous RBCs\n      prepared with the S-303 Treatment System for RBC after storage for 35 days in comparison to\n      conventional untreated RBCs stored for 35 days."
        }, 
        "brief_title": "A Study to Assess the Recovery and Lifespan of Radiolabeled Autologous S 303 Treated Red Blood Cells", 
        "condition": "Focus: Assess Post Infusion Viability of S303 RBCs", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age at least 18 years, of either gender\n\n          -  Normal health status (as determined by the Investigator review of medical history and\n             blood donor physical exam)\n\n          -  Complete blood count (CBC); including red blood cell (RBC) indices mean cell volume\n             (MCV), mean cell hemoglobin (MCH), mean cell hemoglobin concentration (MCHC), and RBC\n             distribution width(RDW) and serum chemistry values within normal limits (including\n             calcium, bicarbonate, chloride, inorganic phosphate, potassium, sodium, cholesterol,\n             glucose, total protein, triglycerides, lactate dehydrogenase (LDH), alanine\n             aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin, blood urea\n             nitrogen (BUN), creatinine). Values outside of normal reference range thought not to\n             be clinically significant may be allowed with a protocol exception.\n\n          -  Minimum hemoglobin levels of 13 g/dL for female and 14.5 g/dL for male subjects\n\n          -  Negative blood donor screening test panel for human immunodeficiency virus (HIV),\n             Hepatitis B virus (HBV), Hepatitis C virus (HCV), human T cell leukemic virus (HTLV),\n             Syphilis, and west nile virus (WNV) (if available)\n\n          -  Female subjects of childbearing potential and male subjects must agree to use a\n             medically acceptable method of contraception throughout the study periods. A barrier\n             method of contraception must be included, regardless of other methods.\n\n          -  Meet or exceed American Association of Blood Banks (AABB) guidelines for blood\n             donation (with the exception of travel deferrals).\n\n          -  Signed and dated informed consent form\n\n        Exclusion Criteria:\n\n          -  \u2022 Clinically significant acute or chronic disease (as determined by the Investigator)\n\n               -  History of RBC autoantibodies/autoimmune hemolytic anemia, RBC allo-antibodies,\n                  or autoimmune disease\n\n               -  History of congenital red cell disorders including glucose 6 phosphate\n                  dehydrogenase (G-6PD) deficiency\n\n               -  Serum ferritin <12 ng/mL\n\n               -  Positive direct antiglobulin test (DAT) or indirect antiglobulin test (IAT) at\n                  study entry\n\n               -  Immunosuppressive therapy (e.g., oral or Intravenous (IV) prednisone) within the\n                  past 28 days\n\n               -  Treatment with any medication known to affect RBC viability\n\n               -  Pregnant or nursing female\n\n               -  Male subjects or female subjects of childbearing potential not using effective\n                  contraception\n\n               -  Participation in another clinical study currently or within the past 28 days\n\n               -  Prior exposure to S 303 treated RBCs\n\n               -  Pre-existing antibody specific to S 303 treated RBCs"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "28", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 17, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01711346", 
            "org_study_id": "CLI 00073"
        }, 
        "intervention": [
            {
                "arm_group_label": "S303 Red Blood Cells (RBCs)", 
                "intervention_name": "S303 Red Blood Cells (RBCs)", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Conventional, Untreated Red Blood Cells (RBCs)", 
                "intervention_name": "Conventional, untreated Red Blood Cells (RBCs)", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "October 17, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Cincinnati", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45267-0055"
                    }, 
                    "name": "Hoxworth Blood Center"
                }, 
                "status": "Completed"
            }, 
            {
                "contact": {
                    "email": "sharon.graminske@bcw.edu", 
                    "last_name": "Sharon Graminske"
                }, 
                "facility": {
                    "address": {
                        "city": "Milwaukee", 
                        "country": "United States", 
                        "state": "Wisconsin", 
                        "zip": "53201"
                    }, 
                    "name": "BloodCenter of Wisconsin Inc."
                }, 
                "investigator": {
                    "last_name": "Jerome L Gottschall, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Controlled, Single-Blind, 2-Period Crossover Study to Assess the Recovery and Lifespan of Radiolabeled Autologous S 303 Treated Red Blood Cells", 
        "overall_official": [
            {
                "affiliation": "Hoxworth Blood Center, Cincinnati, OH", 
                "last_name": "Jose A Cancelas-Perez, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "BloodCenter of Wisconsin, Milwaukee, WI", 
                "last_name": "Jerome L Gottschall, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "24 hour post-infusion recovery of autologous RBCs stored for 35 days (assessed using the Food and Drug Administration (FDA)) criteria for evaluation of  in vivo RBC studies)", 
                "measure": "Primary Efficacy: 24 hour post-infusion recovery of autologous Red Blood Cells (RBCs) stored for 35 days", 
                "safety_issue": "No", 
                "time_frame": "70 Days"
            }, 
            {
                "description": "Incidence of antibody specific to S 303 treated RBCs", 
                "measure": "Primary Safety:  Incidence of antibody specific to S 303 treated Red Blood Cells (RBCs)", 
                "safety_issue": "Yes", 
                "time_frame": "70 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01711346"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Incidence of adverse events", 
                "measure": "Secondary Safety:  Incidence of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "70 Days"
            }, 
            {
                "description": "Mean lifespan of autologous red blood cells (RBCs)", 
                "measure": "Secondary Efficacy Endpoint", 
                "safety_issue": "No", 
                "time_frame": "70 days"
            }, 
            {
                "description": "Median lifespan (T50) of autologous red blood cells (RBCs)", 
                "measure": "Secondary Efficacy Endpoint:", 
                "safety_issue": "No", 
                "time_frame": "70 days"
            }, 
            {
                "description": "Area under the curve (AUC) derived from data points collected for the red blood cell (RBC) lifespan", 
                "measure": "Secondary Efficacy Endpoint", 
                "safety_issue": "No", 
                "time_frame": "70 days"
            }
        ], 
        "source": "Cerus Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Cerus Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}